A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults

Giovanni Luigi Capella, Elena Frigerio, Gianfranco Altomare

Research output: Contribution to journalArticlepeer-review

Abstract

Leukotriene receptor antagonists are recommended for the treatment of asthma, and have proved anecdotally successful even in atopic dermatitis. Standard treatments of atopic dermatitis are often unsatisfactory. Accordingly, we compared montelukast, 10 mg/day, with a combined regimen (orally administered cetirizine and clarythromycin, topical corticosteroids and hydrating preparations) for treatment of moderate-to-severe atopic dermatitis of adults. The trial was designed as a randomized single-blind study. SCORAD, eosinophilic cationic protein (ECP), eosinophilic protein X (EPX) serum levels were assessed at baseline and after 6 weeks in 32 adult patients with atopic dermatitis (16 treated with montelukast; 16 treated with the combined regimen). Similar improvements, evaluated in term of SCORAD reductions, were detected in both groups (Mann-Whitney, p <0.05), while ECP and EPX levels significantly reduced within each group (Welch's approximate t, p <0.05). We conclude that montelukast is as effective as the comparison combined regimen to treat atopic dermatitis of adults.

Original languageEnglish
Pages (from-to)209-213
Number of pages5
JournalEuropean Journal of Dermatology
Volume11
Issue number3
Publication statusPublished - 2001

Keywords

  • Allergic rhinoconjunctivitis
  • Asthma
  • Atopic dermatitis
  • Leukotriene receptor antagonists
  • Montelukast
  • SCORAD

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults'. Together they form a unique fingerprint.

Cite this